EWSR1 Rearrangement and CD99 Expression as Diagnostic Biomarkers for Ewing/PNET Sarcomas in a Moroccan Population

Table 1

Clinical features of enrolled 41 EPS cases.

Case number	Age and sex	Anatomic site	EWSR1 gene rearrangement	CD99 staining
1	26/M	Abdomen	−	+++
2	37/M	Lower limbs	−	+
3	10/F	Head and neck	+	+++
4	40/F	Lower limbs	+	+
5	14/M	Soft tissue	−	+++
6	16/M	Upper limbs	+	−
7	19/M	Lower limbs	+	+
8	10/M	Lower limbs	−	+
9	8/F	Lower limbs	+	+++
10	19/M	Lower limbs	+	+++
11	10/M	Pelvis	−	+
12	13/M	Upper limbs	+	+++
13	38/M	Pelvis	−	+++
14	6/F	Pelvis	IN	+++
15	19/F	Upper limbs	+	+++
16	8/M	Lower limbs	+	+++
17	18/M	Abdomen	−	+++
18	5/M	Thorax	+	+++
19	9/F	Lower limbs	+	+++
20	15/M	Lower limbs	−	+++
21	22/M	Thorax	−	+++
22	11/M	Soft tissue	−	+++
23	23/F	Thorax	+	+++
24	17/M	Thorax	+	+++
25	6/F	Thorax	−	+++
26	21/M	Soft tissue	−	+++
27	18/M	Lower limbs	IN	+
28	21/F	Pelvis	+	+++
29	62/F	Abdomen	−	+
30	28/F	Soft tissue	−	+++
31	29/M	Abdomen	−	−
32	14/M	Lower limbs	+	+++
33	25/M	Upper limbs	+	+++
34	3/M	Lower limbs	+	+++
35	29/M	Pelvis	+	+++
36	28/M	Soft tissue	−	+++
37	50/F	Soft tissue	+	+++
38	40/M	Thorax	−	+
39	62/F	Upper limbs	−	+
40	37/M	Thorax	—	−
41	21/F	Abdomen	+	+++

For EWSR1 rearrangement: positive (+), negative (−), and inconclusive (IN); for CD9 immunostaining: positive staining < 50% (+) and strong, diffuse, and membranous staining ≥ 50% (+++).